Results 61 to 70 of about 2,105 (152)

Complete response after avelumab maintenance therapy: successful management of metastatic urothelial carcinoma

European Journal of Case Reports in Internal Medicine
Urothelial carcinoma is one of the most frequently diagnosed cancer types in the world and despite progress in treatment, it remains a lethal disease in the metastatic stage.
Rita Pinho, Maria João Oura, Francisco Botelho, Inês Nogueira Costa, Miguel Barbosa   +4 more
doaj   +1 more source

Safety and Efficacy of Prophylactic Topical Steroid Administration for Enfortumab Vedotin–related Cutaneous Toxicity

European Urology Open Science
Enfortumab vedotin (EV) is used to treat unresectable/metastatic urothelial carcinoma but often causes cutaneous toxicity (EVRCT) because of Nectin4 expression in the skin, which reduces patients’ quality of life and can lead to dose adjustments or ...
Yuki Kita, Takashi Nomura, Saeko Nakajima, Satoru Yonekura, Kaoru Murakami, Takayuki Sumiyoshi, Kimihiko Masui, Takayuki Goto, Ryoichi Saito, Kenji Kabashima, Takashi Kobayashi   +10 more
doaj   +1 more source

Re-evaluating Treatments for Advanced Urothelial Carcinoma Using Restricted Mean Survival Time: A Systematic Review and Network Meta-analysis

European Urology Open Science
Background and objective: The proportional hazards (PH) assumption may not hold for immune checkpoint inhibitor (ICI) trials because of delayed treatment effects. We assessed PH validity in trials of first-line treatment in advanced urothelial carcinoma (
Shugo Yajima, Wei Chen, Kohei Hirose, Akihiro Hirakawa, Kenji Tanabe, Motohiro Fujiwara, Hiroshi Fukushima, Hajime Tanaka, Hitoshi Masuda, Yasuhisa Fujii, Soichiro Yoshida   +10 more
doaj   +1 more source

Clinical Response to Enfortumab Vedotin and Pembrolizumab in a Patient with Vaginal Squamous Cell Carcinoma: A Case Report

Case Reports in Oncology
Introduction: Vaginal cancer is a rare yet aggressive cancer, with unmet need for novel therapeutics. Case Presentation: In this case report, we present a patient with advanced stage, HPV-positive vaginal cancer who demonstrated clinical ...
Michael Glover, Isabel Beshar, Austin McHenry, Cornelia Ding, Oliver Dorigo, Emily Chan, Sumit A. Shah   +6 more
doaj   +1 more source

Editorial Comment on Comparison of Perioperative Chemotherapy Regimens for Muscle‐Invasive Bladder Cancer: A Reconstructed Individual Patient Data Analysis of Phase 3 Trials

International Journal of Urology, Volume 33, Issue 3, March 2026.
Yusuke Goto
wiley   +1 more source

Mechanistic Insights and Future Directions for Enfortumab Vedotin in Urothelial Carcinoma: Highlights from the 10th Annual Leo & Anne Albert Institute for Bladder Cancer Care and Research Symposium

Current Oncology
Enfortumab vedotin (EV) in combination with pembrolizumab (P) has led to a new paradigm for the treatment of metastatic urothelial carcinoma (mUC). Since the presentation of the results of the EV-302 trial at the European Society of Medical Oncology 2023
Catherine C. Fahey, Sean Clark-Garvey, Sima Porten, Ashish M. Kamat, Thomas W. Flaig, John A. Taylor, William Y. Kim, Matthew I. Milowsky   +7 more
doaj   +1 more source

Efficacy and safety of antibody-drug conjugates in the treatment of advanced urological cancers: a systematic review and a meta-analysis

Frontiers in Pharmacology
BackgroundAntibody-drug conjugates (ADCs) offer novel therapeutic options for advanced urological cancers, but their efficacy and safety vary across cancer types.
Tian Liu, Xiao Xie, Yangz-Zi Ren, Zongyu Li, Maoping Cai, Yuzhong Yu, Lin Zhuo   +6 more
doaj   +1 more source

Antibody-drug conjugates targeting the cadherin, claudin and nectin families of adhesion molecules

Frontiers in Molecular Medicine
The classical cadherin (CDH), claudin (CLDN) and nectin families of transmembrane-type adhesion molecules are located at adherens or tight junctions in epithelial cells but diffuse to the nonjunctional cell surface in solid tumors with epithelial ...
Masuko Katoh, Yohann Loriot, Yohann Loriot, Izuma Nakayama, Akinobu Hamada, Akinobu Hamada, Kohei Shitara, Masaru Katoh, Masaru Katoh, Masaru Katoh   +9 more
doaj   +1 more source

Systemic Toxicity With Hyperglycemia or Diabetic Ketoacidosis After Enfortumab Vedotin: Single-Center Case Series

Annals of Internal Medicine: Clinical Cases
Enfortumab vedotin (EV) revolutionized management of metastatic urothelial carcinoma. Multiple-organ dysfunction is a rare adverse event associated with EV with unknown mechanisms.
Mohammad Jad Moussa, Nathaniel R. Wilson, Anindita Ghosh, Meenakshi B. Bhattacharjee, Jonathan L. Curry, Woo Cheal Cho, Anisha B. Patel, Mouhammed Amir Habra, Sonali N. Thosani, Matthew T. Campbell, Arlene O. Siefker-Radtke, Omar Alhalabi, Nupur J. Kikani   +12 more
doaj   +1 more source

Enfortumab Vedotin [PDF]

, 2020
openaire   +1 more source